CSL

Responsable Hospitalier Maladies Rares - Hauts-de-France / Normandie

France

Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, Healthcare, Rare DiseasesIndustries

Requirements

The candidate should possess a strong knowledge of the field of rare diseases and the complexity of its ecosystem, as well as the evolution of patient journeys, including diagnostic procedures, therapeutic decisions, and treatment selection. Experience in planning, executing, and implementing the launch and commercialization of products for rare diseases is required, along with a strategic approach to territory management and a deep understanding of the pharmaceutical regulatory landscape and legal obligations.

Responsibilities

The Responsable Hospitalier Maladies Rares will be responsible for deploying the commercial strategy locally, serving as the primary point of contact for healthcare professionals, and managing clients through an omnichannel approach. They will promote Vifor products and encourage their appropriate use, adhering to the Pharmaceutical Information Charter and the current Certification Framework. The role involves contributing to sales projections, collaborating with market access functions to ensure patient access to treatment, fostering a customer-centric culture, and maintaining a thorough understanding of patients, the broader care landscape, and the competitive environment. Furthermore, the position requires creating a cross-functional work environment and ensuring exemplary customer experience, reflecting Vifor France as a trusted partner.

Skills

Rare diseases knowledge
Diagnostic procedures
Therapeutic decisions
Treatment selection
Commercial strategy development
Communication
Interpersonal skills
Cross-functional collaboration
Pharmaceutical regulations
Legal/regulatory compliance
Data-driven decision making
CRM tools

CSL

Develops biotherapies and influenza vaccines

About CSL

CSL develops and delivers biotherapies and influenza vaccines, focusing on rare and serious diseases. Their products include plasma-derived and recombinant therapies, which are created through extensive research and development. CSL serves a wide range of clients, including healthcare providers and governments, across the Americas, Asia Pacific, and Europe. What sets CSL apart from competitors is its comprehensive portfolio and commitment to addressing rare diseases, alongside a strong emphasis on diversity and inclusion within its workforce. The company's goal is to save lives and protect health through its innovative therapies and vaccines.

Key Metrics

Parkville, AustraliaHeadquarters
1916Year Founded
$2,628.7MTotal Funding
ACQUISITIONCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Risks

Emerging synthetic biomaterials may reduce demand for traditional plasma therapies.
Jumar Bioincubator could increase local competition in the biotech sector.
CSL may need to adapt to the rising effectiveness of cell-based influenza vaccines.

Differentiation

CSL offers the broadest range of plasma-derived and recombinant therapies globally.
CSL's self-amplifying mRNA COVID-19 vaccine provides longer immunity at lower doses.
CSL's MF59® adjuvant enhances immune response, crucial for pandemic preparedness.

Upsides

CSL's garadacimab could be the first monthly treatment for hereditary angioedema.
CSL's cell-based influenza vaccine shows higher effectiveness over egg-based vaccines.
CSL's gene therapy HEMGENIX® offers a one-time treatment for haemophilia B.

Land your dream remote job 3x faster with AI